Pfizer

Yahoo Finance • 2 hours ago

What the U.S. Pharmaceutical Industry Could Learn from How Africa Solves Patient Access

A veteran of Pfizer, Sanofi, and Novo Nordisk who built patient access programmes across West Africa argues that the $500 billion medication adherence crisis plaguing American healthcare has already been solved - in markets the industry ha... Full story

Yahoo Finance • 3 hours ago

Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best

This article first appeared on GuruFocus. It isn't often that a nearly $1 trillion company moves with the volatility of a speculative biotech, but that is exactly what I am seeing today as Eli Lilly drops its Q1 2026 results. The stock ha... Full story

Yahoo Finance • 22 hours ago

Thinning revenues: inside the $14bn Eliquis patent cliff

Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected this year for Europe and in 2027 for the US and Japan. With global sales of $... Full story

Yahoo Finance • 22 hours ago

Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales

By Michael Erman and Puyaan Singh April 30 (Reuters) - Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by better-than-expected growth of blood thinner Eliquis ‌and newer cancer m... Full story

Yahoo Finance • yesterday

Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, resolving patent infri... Full story

Yahoo Finance • 2 days ago

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started

PatentVest, Inc. Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.” In A... Full story

Yahoo Finance • 2 days ago

ISG Future Workplace Summit to Explore How AI Is Transforming Work, Skills and Leadership

Leaders with LinkedIn, McDonald’s, Dentsu, Pfizer, PepsiCo, Royal Caribbean, Wayfair, New York Life and more to discuss AI-driven workplace transformation STAMFORD, Conn., April 29, 2026--(BUSINESS WIRE)--Information Services Group (ISG)... Full story

Yahoo Finance • 2 days ago

OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...

This article first appeared on GuruFocus. Revenue: $124.2 million for Q1 2026, down from $149.9 million in Q1 2025. Diagnostics Revenue: $72.2 million in Q1 2026, including $6.5 million from 4K score test. Pharmaceutical Revenue: $52 mill... Full story

Yahoo Finance • 3 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomla... Full story

Yahoo Finance • 3 days ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks edged up late Tuesday afternoon, with the NYSE Health Care Index fractionally hig PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon

Health care stocks edged up Tuesday afternoon, with the NYSE Health Care Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 days ago

Should You Buy, Sell, or Hold Pfizer at $27?

Pfizer (NYSE: PFE) has been a pharmaceutical giant for decades and a key player in healthcare. Its drugs have saved lives and generated a ton of revenue for its business over the years. While it's still innovating and developing new treatm... Full story

Yahoo Finance • 3 days ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

NEW YORK, April 28, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed... Full story

Yahoo Finance • 3 days ago

FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States

FormBlends Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the fastest-moving area of American metabolic and longevity medicine. MIAMI, FL, April 28, 2026 (GLOBE NEWSWIRE... Full story

Yahoo Finance • 3 days ago

ESR1 Mutated Metastatic Breast Cancer Market Research Report 2026: Epidemiological Analysis, Competitive Landscape, Regulatory Landscape, Pipeline Analysis, M&A, Regulatory Activities, Funding,

Company Logo The metastatic breast cancer (mBC) landscape is evolving rapidly due to the increasing prevalence of ESR1 mutations, a key driver for hormone receptor-positive (HR+) patients. ESR1 mutations, particularly in the ligand-bindin... Full story

Yahoo Finance • 3 days ago

Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma

Company Logo The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs, rare tumors originating... Full story

Yahoo Finance • 3 days ago

Gastroesophageal Adenocarcinoma Market Research Report 2026, Competitive Analysis of ALX Oncology, Merck, AstraZeneca, BeOne Medicines, Taiho Pharmaceuticals, Eli Lilly - Global Forecast to 2035

Company Logo Gastroesophageal adenocarcinoma (GEA), a cancer prevalent in the esophagus' glandular cells or stomach's gastroesophageal junction, is on the rise due to risk factors like GERD, obesity, and smoking. This aggressive cancer is... Full story

Yahoo Finance • 4 days ago

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Organon(NYSE:OGN), a women’s health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutical Industries agreed to acquire Organon in an all-cash deal. Trading volume reache... Full story

Yahoo Finance • 4 days ago

Is Bristol Myers Squibb the Best Bargain in Big Pharma?

Every American knows that healthcare isn't cheap. Healthcare costs continue to rise. Some healthcare stocks are cheap, though, including the stocks of some of the world's biggest drugmakers. Bristol Myers Squibb (BMS) (NYSE: BMY) is one o... Full story

Yahoo Finance • 6 days ago

Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know.

Shares of Pfizer(NYSE: PFE) have fallen 55% from their late 2021 high. That decline highlights a material change in Wall Street's view of the pharmaceutical giant. And it has pushed the dividend yield up to a lofty 6.3%. Is the dividend ac... Full story